Key features and details
- Rabbit polyclonal to Osteoprotegerin
- Suitable for: Sandwich ELISA, WB
- Reacts with: Mouse, Human
- Isotype: unknown
Product nameAnti-Osteoprotegerin antibody
See all Osteoprotegerin primary antibodies
DescriptionRabbit polyclonal to Osteoprotegerin
Tested applicationsSuitable for: Sandwich ELISA, WBmore details
Species reactivityReacts with: Mouse, Human
Highly pure (>98%) recombinant hOPG (human Osteoprotegerin)
This product is no longer batch tested in IHC, for an IHC validated antibody please see ab124820
FormLyophilized:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.40
No preservative, sterile filtered
Concentration information loading...
PurityImmunogen affinity purified
Light chain typeunknown
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab9986 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration.
To detect hOPG by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with ab271213 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hOPG.
|WB||Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 46 kDa).Can be blocked with Recombinant Human Osteoprotegerin protein (ab110188).
To detect hOPG by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hOPG is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
FunctionActs as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Tissue specificityHighly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in diseaseDefects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
Sequence similaritiesContains 2 death domains.
Contains 4 TNFR-Cys repeats.
modificationsN-glycosylated. Contains sialic acid residues.
The N-terminus is blocked.
- Information by UniProt
- MGC29565 antibody
- OCIF antibody
- OPG antibody
All lanes : Anti-Osteoprotegerin antibody (ab9986) at 1 µg/ml
Lane 1 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
Lane 2 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 46 kDa
Observed band size: 56 kDa why is the actual band size different from the predicted?
Additional bands at: 32 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 150 seconds
Osteoprotegerin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab9986 has been referenced in 10 publications.
- Mao Z et al. MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. IUBMB Life N/A:N/A (2019). PubMed: 31317664
- Navet B et al. The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases. Cancers (Basel) 10:N/A (2018). PubMed: 30355966
- Shen MJ et al. Nell-1 Enhances Osteogenic Differentiation of Pre-Osteoblasts on Titanium Surfaces via the MAPK-ERK Signaling Pathway. Cell Physiol Biochem 50:1522-1534 (2018). PubMed: 30359975
- Abu El-Asrar AM et al. Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci 58:3189-3201 (2017). PubMed: 28654984
- Vaziri-Sani F et al. Osteoprotegerin autoantibodies do not predict low bone mineral density in middle-aged women. Bone Rep 7:132-136 (2017). PubMed: 29124083
- Takei Y et al. Osteoclastogenic Differentiation of Macrophages in the Development of Abdominal Aortic Aneurysms. Arterioscler Thromb Vasc Biol 36:1962-71 (2016). PubMed: 27386936
- Peng L et al. Lentivirus-mediated TNF-a gene silencing and overexpression of osteoprotegerin inhibit titanium particle-induced inflammatory response and osteoclastogenesis in vitro. Mol Med Rep 13:1010-8 (2016). PubMed: 26648171
- Xi L et al. OPG/RANK/RANKL axis in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cardiology 124:18-24 (2013). PubMed: 23295350
- Mediero A et al. Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci Transl Med 4:135ra65 (2012). IHC-P ; Mouse . PubMed: 22623741
- Byron CR et al. In vitro expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in cultured equine articular cells. Am J Vet Res 71:615-22 (2010). WB, ICC ; Horse . PubMed: 20513175